Jump to content

Mahana obtains marketing authorization for IBS digital therapeutic - Healio

Health Reporter

Recommended Posts

Mahana obtains marketing authorization for IBS digital therapeutic  Healio

Parallel, a prescription digital therapeutic developed by Mahana Therapeutics for the treatment of irritable bowel syndrome, received marketing authorization from the FDA, according to a company press release.

The 3-month digital program uses cognitive behavioral therapy to help adults change factors that might contribute to IBS.

“Parallel provides adult patients suffering from any subtype of IBSwith a clinically validated, digitally delivered, cognitive behavioral therapy-based complementary treatment,” Emeran Mayer, MD, a distinguished professor at UCLA, and member of Mahana’s clinical advisory board, said in the release. “Cognitive behavioral therapy has increasingly been incorporated into gastrointestinal patient care, and this digital model increases access to this important treatment approach. Prescription digital therapeutics, working in ‘parallel’ with medications and other treatments represent an exciting new frontier in medicine.”

View the full article

Link to comment
Share on other sites

  • Jeffrey Roberts changed the title to Mahana obtains marketing authorization for IBS digital therapeutic - Healio

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...